News | Nuclear Imaging | December 14, 2020

The Journal of Nuclear Medicine Celebrates 60 Years of Research

JNM celebrates 60 years of nuclear medicine research. Image courtesy of Society of Nuclear Medicine and Molecular Imaging.

December 14, 2020 — The Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.

The supplement features a collection of the most influential and frequently cited manuscripts in JNM's history, representing seminal discoveries and scientific contributions that shaped the future of medicine. Invited perspectives from world leaders in nuclear medicine, molecular imaging, and theranostics explain why each of these articles had such an enormous impact.

Highlights include milestone articles on the invention of the Anger camera, the creation of positron emission tomography (PET) and 18F-FDG, the development of fusion PET/CT, the introduction of FDG PET-based response criteria in solid tumors, and many more landmark papers that have shaped the history of nuclear medicine.

Moving from the past to the present and beyond, the special issue concludes with the JNM associate editors' views on the most promising future applications of nuclear medicine. "We hope to demonstrate that the field not only is highly relevant for diagnosing and understanding the pathophysiology of human diseases but also is increasingly becoming an integral part of patient management," they said.

"Our collective success is rooted in the research that scientists from around the globe submit to JNM, the tireless efforts of reviewers and editorial board members, and the commitment and interest of readers," said JNM Editor-in-Chief Johannes Czernin, M.D. "Substantial credit for the success of JNM also goes to its past editors, who each made unique contributions to establish JNM as the world's leading journal on nuclear medicine and molecular imaging."

For more information:

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Maste